LYTIC LESION OF A DIGIT COULD BE A METASTASIS FROM LUNG. A RARE CASE REPORT

Tanveer Ahmed Bhat∗,1, Mir Mohsin∗, Nahida Yousuf∗∗, Hatan Mortada∗∗∗, Israh Alzarmah∗∗∗, Duaa Nasser Almansour∗∗∗, Hisham Alokaili∗∗∗, Tareg Mansour∗∗∗, Tuqa Alsinan∗∗∗ and Khadija Mustafa∗∗∗

∗Department of Plastic Surgery SKIMS Soura Srinagar Kashmir, India., ∗∗Department of Radiation Oncology, GMC Srinagar Kashmir, India., ∗∗∗Department of Plastic Surgery, KSMC Riyadh Saudi Arabia.

ABSTRACT

Acral bone metastasis from lung carcinoma to the upper and lower extremities are uncommon accounting for only 1% each of total bone metastases from carcinoma of the lung. Usually, acrometastasis is a sign of a very advanced disease with a presence of previous metastases elsewhere. The present paper is one of the very few case reports of the first metastatic location to phalanges of the ring finger of the right hand. A 70-year-old male was submitted to several physical examinations for painful swelling of the tip of the right ring finger. On X-ray a lytic lesion was found in the distal phalanx of the ring finger and on open biopsy, it revealed deposits of adenocarcinoma. A total body computed tomography was done which showed right lung mass.

KEYWORDS Acrometastasis, CA Lung, Adenocarcinoma

Introduction

Metastasis to the bones of the fingers means Stage IV of the primary carcinoma. It is very rare, but it implies a very advanced disease when it occurs. Most bony metastases, including non-digital acrometastatic disease, arise from many primary tumours (e.g., prostate, lung, kidney, breast, gastrointestinal). Unless proved otherwise, the aetiology of digital acrometastases is almost exclusively bronchogenic carcinoma[1]. Luckily digital acrometastatic lung cancer is seldom seen, accounting for approximately one out of 500 lung cancers with bony metastases[2]. The prognosis is grim, with a mean survival of three to six months after presentation.[3,4]

Case report

A 70-year-old elderly man, the chronic smoker, presents with a swollen, erythematous, painful tip of the right ring finger. Patient consulted a local physician who prescribed a course of antibiotics and anti-inflammatory drugs as it presented as an inflammatory swelling. However, the patient did not respond, and the swelling persisted, and the erythema worsened. A hand radiograph was ordered, which showed a highly aggressive lytic lesion involving the distal phalanx with permeative margins and a slight immature periosteal reaction. There was significant associated soft tissue swelling or mass and an associated minimally displaced pathologic fracture through the midportion of the phalanx. Additionally, there were adjacent tiny ossific or calcific fragments, possibly displaced bony fragments or dystrophic soft tissue calcification. An open biopsy of the lytic lesion was done, which showed deposits of the adenocarcinoma. The patient was referred to the general medicine department evaluated for occult primary. Baseline investigations were done, followed by whole-body computed tomography, which showed right lung mass. The patient was referred to the medical oncology department for further management.

Figure 1 Dorsal aspect of hand showing a swelling in the distal phalanx of ring finger.

Discussion

Acrometastasis is very uncommon, with only one out of 1000 bony metastases travelling to the hand.[5] In order of prevalence, primary malignant lesions from the lung, kidney, breast, and gastrointestinal tract are implicated in it [6]. Men are more likely to be affected than women, with solitary phalangeal lesions commonly observed.[4] The route of spread from the primary malignant to hand bones is hematogenous.[6] The hepatic and pulmonary capillary beds restrict the wide hematogenous spread of many visceral organ malignancies very often. However, malignant cells of the lung have unimpeded access to the distal arterial
Conclusion

Though the metastasis from lung to small bones of the hand is very rare, a high suspicion should be kept in mind while dealing with the lytic lesions of the hand in high-risk patients like elderly chronic smokers.

Funding

This work did not receive any grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest

There are no conflicts of interest to declare by any of the authors of this study.

References

1. C. M. Galmarini, A. Kertesz, R. Oliva, J. Porta, and F. C. Galmarini, “Metastasis of bronchogenic carcinoma to the thumb,” Medical Oncology, vol. 15, no. 4, pp. 282–285, 1998.
2. P. P. Kumar, “Metastases to the bones of the hand,” Journal of the National Medical Association, vol. 67, no. 4, pp. 275–276, 1975.
3. M. Heidarpour, P. Rajabi, A. Eftekhar, and H. R. Ghasemibasir, “Lung carcinoma metastasis to the distal part of the index finger: a case report,” Iran Journal of Pathology, vol. 1, pp. 173–176, 2006.
4. C. J. Flynn, C. Danjoux, and C. Danjoux, “Two cases of acrometastasis to the hands and review of the literature,” Current Oncology, vol. 15, no. 5, pp. 51–58, 2008.
5. R. Kerin, “Metastatic tumors of the hand. A review of the literature,” Journal of Bone and Joint Surgery. Series A, vol. 65, no. 9, pp. 1331–1335, 1983.
6. G. Asencio, CH. Hafdi, H. Pujol, and Y. Allieu, “Osseous metastases in the hand. A general review of three cases,” Annales de Chirurgie de la Main, vol. 1, no. 2, pp. 137–145, 1982.
7. R. Baran, P. Guillot, and A. Tosti, “Metastasis from carcinoma of the bronchus to the distal aspect of two digits,” British Journal of Dermatology, vol. 138, no. 4, p. 708, 1998.
8. N. Khokhar and J. D. Lee, “Phalangeal metastasis: first clinical sign of bronchogenic carcinoma,” Southern Medical Journal, vol. 76, no. 7, p. 927, 1983.
9. H. Nakamura, T. Shimizu, K. Kodama, and H. Shimizu, “Metastasis of lung cancer to the finger: a report of two cases,” International Journal of Dermatology, vol. 44, no. 1, pp. 47–49, 2005.
10. R. Kerin, “The hand in metastatic disease,” Journal of Hand Surgery, vol. 12, no. 1, pp. 77–83, 1987.
11. N. Pavlakis, R. Schmidt, and M. Stockler, “Bisphosphonates for breast cancer,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD003474, 2005.
12. M. R. Smith, B. Egerdie, and B. Egerdie, “Denosumab in men receiving androgen-deprivation therapy for prostate cancer,” New England Journal of Medicine, vol. 361, no. 8, pp. 745–755, 2009.